This invention relates to nanomedicine formulation comprised of undoped or metal cluster doped protein nanoparticles loaded with a tyrosine kinase inhibitor, sorafenib. The loading of sorafenib in the protein nanoparticles greatly improves its solubility in bio-fluid whereby improving its bioavailability and therapeutic efficacy. Additionally, the protein nanoparticles can be targeted specifically to the disease site by conjugating active biomolecules such as antibodies, peptides, small sugar molecules, vitamins, etc. The proteins selected for the nanoparticle preparations are derived from natural sources and are highly biocompatible. The protein nanoparticles are preferably doped with nanosized atomic clusters of gold, copper, iron, platinum or silver for imparting improved properties such as optical contrast, magnetic contrast, modulation of zeta potential and desired pharmacokinetics. The metal nanocluster doped protein nanoparticles loaded/embedded with sorafenib possess altered surface charge enabling enhanced renal clearance, whereas, the undoped protein nanoparticles carrying sorafenib adopt a hepatic route of clearance.
A. Vishwa Vidyapeetham, “Nanoparticles comprising sorafenib”, U.S. Patent PCT/IN2012/0007872014.